Eupraxia Pharmaceuticals (EPRX) Total Current Liabilities (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Total Current Liabilities of $7.4 million for Q1 2026, up 30.82% quarter-over-quarter from $5.6 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Total Current Liabilities (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Total Current Liabilities for 5 consecutive years, with $7.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities changed N/A year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (changed N/A YoY), while the FY2025 annual figure was $5.6 million, up 81.35% from the prior year.
- Total Current Liabilities climbed to $7.4 million in Q1 2026 per EPRX's latest filing, from $5.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $19.4 million in Q4 2023 and bottomed at $2.4 million in Q3 2024.
- Historically, Total Current Liabilities has averaged $7.0 million across 5 years, with a median of $4.7 million in 2025.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 533.47% — and 2024, when it sank 83.98%.
- Eupraxia Pharmaceuticals' Total Current Liabilities stood at $3.1 million in 2022, then jumped by 533.47% to $19.4 million in 2023, then tumbled by 83.98% to $3.1 million in 2024, then soared by 81.35% to $5.6 million in 2025, then soared by 30.82% to $7.4 million in 2026.
- Business Quant data shows EPRX's Total Current Liabilities at $7.4 million in Q1 2026, $5.6 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 7.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.36 Mn |
| Dec 31, 2025 | 5.63 Mn |
| Sep 30, 2025 | 3.81 Mn |
| Dec 31, 2024 | 3.10 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 11.60 Mn |
| Dec 31, 2023 | 19.37 Mn |
| Dec 31, 2022 | 3.06 Mn |